Search results
Showing 51 to 100 of 8100 results
1. Provisional appraisal topics chosen The NICE topic selection programme produces a list of provisional appraisal topics. 2. Stakeholders identified
On this page, you'll find a list of all our position statements relating to our technology appraisal guidance. Biosimilar technologies: NICE position
A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by social workers in different settings.
Evidence-based recommendations on Kurin Lock for blood culture collection.
View recommendations for MTG77Show all sections
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
View recommendations for MTG78Show all sections
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)
Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.
View recommendations for IPG784Show all sections
NICE is unable to make a recommendation on sebelipase alfa (Kanuma) for treating lysosomal lipase deficiency that is not Wolman disease in adults. The Wolman disease population was evaluated separately in NICE highly specialised technology guidance on sebelipase alfa (HST30). The cost effectiveness of the remaining non-Wolman population has not been demonstrated at this stage.
Show all sections
Sections for TA961
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)
NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.
Show all sections
Sections for TA965
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Find out more about supporting a quality standard at NICE.
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
NICE is unable to make a recommendation on satralizumab (Enspryng) for preventing relapses in neuromyelitis optica spectrum disorders in adults
Show all sections
Sections for TA960
Information, meeting dates and minutes of the medical technologies advisory committee
Find out more about the medical technologies advisory committee members by reading their biographies. Dr Jacob Brown (chair) Biography Jacob
What we do NICE has a key role in the evaluation of and access to new and innovative medicines and treatments for the health system, playing an...
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence
The key stages of development for quality standards
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
Summary of the evidence on desflurane for maintenance of anaesthesia
Find out more about NICE's new proportionate approach to technology appraisals
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people....
View recommendations for HTE17Show all sections
This indicator covers the proportion of people with dementia prescribed anti-psychotic medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG18
Pregnancy and neonates: mental health at booking appointment
This indicator covers proportion of pregnant women who were asked about their mental health at their first booking appointment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG82
This indicator covers mortality rates directly associated with VTE. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG80
Gynaecological conditions: rates of endometrial ablation (heavy menstrual bleeding)
This indicator covers rates of endometrial ablation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG78
Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding)
This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
Agenda and papers of the NICE public board meeting on 20 March 2024
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
Our board meetings are open to the public. You can download the agenda, papers and minutes for each meeting.
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....
Resources to help organisations who want to help develop NICE guidance
Take part in the production of medical technologies guidance.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
We're bringing our guidance together by topic, so that it's all in one place, clearer to understand and easier to access. We expect that this will...
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA
Changes to charging for Technology Appraisal and Highly Specialised Technologies consultation
Take part in our consultation: 5 proposals about the way the NICE charges for TAs and HSTs.
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.